Veraxa Biotech is trading 5.2% up at $2.25 today after announcing an AI-enabled drug discovery collaboration with Ardigen to support its BiTAC pipeline. The partnership aims to develop AI-driven tools and models to guide the selection of dual cancer target pairs for its novel BiTAC platform. This positive development follows recent volatility for the company, which saw a new interim CFO appointed on July 10, 2026, and its Nasdaq debut on June 11, 2026, after a SPAC merger.